Author
S. Taranto
Bio: S. Taranto is an academic researcher. The author has contributed to research in topics: Transplantation & Kidney disease. The author has an hindex of 11, co-authored 12 publications receiving 2176 citations.
Papers
More filters
TL;DR: There has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors since 1988.
Abstract: Background The introduction of cyclosporine has resulted in improvement in the short-term outcome of renal transplantation, but its effect on the long-term survival of kidney transplants is not known. Methods We analyzed the influence of demographic characteristics (age, sex, and race), transplant-related variables (living or cadaveric donor, panel-reactive antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of acute rejection, delayed graft function, and therapy with mycophenolate mofetil and tacrolimus) on graft survival for all 93,934 renal transplantations performed in the United States between 1988 and 1996. A regression analysis adjusted for these variables was used to estimate the risk of graft failure within the first year and more than one year after transplantation. Results From 1988 to 1996, the one-year survival rate for grafts from living donors increased from 88.8 to 93.9 percent, and the rate for cadaveric grafts increased...
1,723 citations
TL;DR: The long-term survival of SKPT recipients is superior to that of cadaver kidney transplant recipients with type 1 diabetes, and results suggest that successful simultaneous kidney-pancreas transplantation is not only life enhancing, but life saving.
209 citations
University of Pittsburgh1, Duke University2, University of Alabama at Birmingham3, University of Colorado Denver4, Albany Medical College5, Indiana University6, National Institutes of Health7, Harvard University8, Icahn School of Medicine at Mount Sinai9, Boston Children's Hospital10, Cleveland Clinic11, University of Rochester12, University of Miami13, University of Virginia14, University of Michigan15
TL;DR: There was a 43% increase in the number of PDDTE reported and reviewed in 2013 over 2012, however, the percent with P/P transmission remains low, affecting recipients from 32 donors especially when compared with the more than 14,000 donors recovered annually in the United States.
Abstract: BackgroundThe Organ Procurement Transplant Network Disease Transmission Advisory Committee (DTAC), a multidisciplinary committee, evaluates potential donor-derived transmission events (PDDTE), including infections and malignancies, to assess for donor transmitted events.MethodsReports of unexpected
88 citations
TL;DR: The rationale of using PHS donor designation that negatively impacts utilization of high-quality organs without the benefit of identifying the subset of organs with demonstrable proclivity to transmit HIV, HBV, or HCV needs to be reexamined.
Abstract: BackgroundIn 2013, the public health service (PHS) changed the criteria intended to identify organ donors that put the associated organ recipients at increased risk for acquiring human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). The changing donor demographics
49 citations
Cited by
More filters
TL;DR: This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
Abstract: Suppression of allograft rejection is central to successful organ transplantation; thus, immunosuppressive agents are crucial for successful allograft function. Immunosuppressive drugs are used for induction (intense immunosuppression in the initial days after transplantation), maintenance, and reversal of established rejection. This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
1,342 citations
TL;DR: This work analyzed data provided by the Scientific Registry of Transplant Recipients regarding all adult first renal transplants between 1995 and 2000 to investigate how acute rejection rates have evolved on a national level in the U.S and how this has impacted graft survival in the most recent era of kidney transplantation.
1,157 citations
TL;DR: A systematic review of studies comparing adult chronic dialysis patients with kidney transplantation recipients for clinical outcomes found significantly lower mortality associated with transplantation, and the relative magnitude of the benefit seemed to increase over time.
1,027 citations
TL;DR: Current antirejection therapy, including calcineurin blockers such as cyclosporine and tacrolimus, the interleukin-2 signal-transduction inhibitor sirolimus and the purine-synthesis inhibitor mycophenolate mofetil are discussed, which inhibits the proliferation of T cells and B cells.
Abstract: This article provides a comprehensive, up-to-date review of methods to prevent early and late renal-allograft loss and to improve long-term outcomes in patients. The authors focus particular attention on the problem of late graft loss and discuss current antirejection therapy, including calcineurin blockers such as cyclosporine and tacrolimus, the interleukin-2 signal-transduction inhibitor sirolimus, and the purine-synthesis inhibitor mycophenolate mofetil, which inhibits the proliferation of T cells and B cells.
830 citations
TL;DR: Recent improvements in graft half-life are related to conservation of renal function within the first year post-transplantation, and one-year creatinine and Delta Creatinine values predict long-term renal graft survival.
683 citations